tiprankstipranks
Sichuan Kelun-Biotech Receives Approval for Investigational Drug SKB445
Company Announcements

Sichuan Kelun-Biotech Receives Approval for Investigational Drug SKB445

Story Highlights

Invest with Confidence:

The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that it has received approval from the National Medical Products Administration for its investigational new drug application for SKB445, a novel ADC drug. SKB445, developed using the company’s OptiDC platform, has shown promising preclinical results for the treatment of advanced solid tumors, marking a significant step forward in the company’s drug development efforts.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, specializing in the development of innovative drugs, particularly in the area of advanced solid tumors. The company utilizes its proprietary OptiDC platform technology to develop novel ADC drugs.

YTD Price Performance: -0.43%

Average Trading Volume: 306,248

Technical Sentiment Consensus Rating: Hold

Current Market Cap: HK$36.23B

For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles